KR20150004416A - 면역 반응의 조절 - Google Patents

면역 반응의 조절 Download PDF

Info

Publication number
KR20150004416A
KR20150004416A KR20147033632A KR20147033632A KR20150004416A KR 20150004416 A KR20150004416 A KR 20150004416A KR 20147033632 A KR20147033632 A KR 20147033632A KR 20147033632 A KR20147033632 A KR 20147033632A KR 20150004416 A KR20150004416 A KR 20150004416A
Authority
KR
South Korea
Prior art keywords
sting
cells
dna
nucleic acid
trex1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20147033632A
Other languages
English (en)
Korean (ko)
Inventor
글렌 엔. 바버
Original Assignee
글렌 엔. 바버
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/460,408 external-priority patent/US20130039933A1/en
Application filed by 글렌 엔. 바버 filed Critical 글렌 엔. 바버
Publication of KR20150004416A publication Critical patent/KR20150004416A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR20147033632A 2012-04-30 2013-04-30 면역 반응의 조절 Ceased KR20150004416A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/460,408 2012-04-30
US13/460,408 US20130039933A1 (en) 2008-08-04 2012-04-30 Sting (stimulator of interferon genes), a regulator of innate immune responses
PCT/US2013/038840 WO2013166000A1 (en) 2012-04-30 2013-04-30 Modulating immune responses

Publications (1)

Publication Number Publication Date
KR20150004416A true KR20150004416A (ko) 2015-01-12

Family

ID=49514802

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147033632A Ceased KR20150004416A (ko) 2012-04-30 2013-04-30 면역 반응의 조절

Country Status (7)

Country Link
EP (1) EP2844756A4 (https=)
JP (1) JP2015516989A (https=)
KR (1) KR20150004416A (https=)
CN (1) CN104540945A (https=)
AU (1) AU2013256468A1 (https=)
CA (1) CA2907616A1 (https=)
WO (1) WO2013166000A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
CN106540260A (zh) * 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
CN106539757A (zh) * 2016-03-20 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
CN106667914B (zh) * 2017-03-13 2022-02-01 杭州星鳌生物科技有限公司 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
EP3691640A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Methods for administering sting agonists
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
US11535633B2 (en) 2018-06-28 2022-12-27 Jiangsu Hengrui Medicine Co., Ltd. Fused tricyclic heterocycle compounds and therapeutic uses thereof
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP4077318B1 (en) 2019-12-18 2025-10-15 Ctxt Pty Ltd Benzimidazole dimers as modulators of sting
EP4075980B1 (en) 2019-12-18 2025-07-23 Stinginn LLC Substituted 1,2, 4-triazoles and methods of use
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
WO2025262266A1 (en) 2024-06-21 2025-12-26 Institut National de la Santé et de la Recherche Médicale Methods of determining the clinical phenotype of patients suffering from hidradenitis suppurativa

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529708A (ja) * 2008-08-04 2011-12-15 ユニバーシティ オブ マイアミ 自然免疫応答の調節因子ｓｔｉｎｇ（インターフェロン遺伝子の刺激因子）

Also Published As

Publication number Publication date
JP2015516989A (ja) 2015-06-18
CA2907616A1 (en) 2013-11-07
EP2844756A4 (en) 2016-02-24
EP2844756A1 (en) 2015-03-11
AU2013256468A1 (en) 2014-12-04
WO2013166000A1 (en) 2013-11-07
CN104540945A (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
KR20150004416A (ko) 면역 반응의 조절
US20200392492A1 (en) Modulating Immune Responses
Fox et al. p53 and ATF4 mediate distinct and additive pathways to skeletal muscle atrophy during limb immobilization
Greco et al. Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy
JP7503558B2 (ja) 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法
Zhang et al. Sirtuin 6 inhibits myofibroblast differentiation via inactivating transforming growth factor‐β1/Smad2 and nuclear factor‐κB signaling pathways in human fetal lung fibroblasts
Kavazis et al. Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle
Chen et al. Stat5-dependent cardioprotection in late remote ischaemia preconditioning
US9814741B2 (en) Methods relating to DNA-sensing pathway related conditions
Tao et al. KPNA2 interacts with P65 to modulate catabolic events in osteoarthritis
US9845471B2 (en) Compositions and methods for treating pancreatic cancer
Liu et al. POLR2A blocks osteoclastic bone resorption and protects against osteoporosis by interacting with CREB1
Mohamed et al. Na+/H+ exchanger isoform 1-induced osteopontin expression facilitates cardiomyocyte hypertrophy
Araujo et al. Prostatic acid phosphatase is the main acid phosphatase with 5′-ectonucleotidase activity in the male mouse saliva and regulates salivation
Liu et al. Inhibiting checkpoint kinase 1 protects bone from bone resorption by mammary tumor in a mouse model
Suzuki et al. Manipulating histone acetylation leads to antitumor effects in hemangiosarcoma cells
Tokumoto et al. Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth
Levesque et al. Inflamed endothelial cells express S1PR1 inhibitor CD69 to induce vascular leak
WO2022137964A1 (ja) 軟骨・骨・関節疾患の予防または治療用医薬組成物および軟骨・骨・関節疾患の予防または治療用薬剤のスクリーニング方法
Tang et al. p53 peptide prevents LITAF-induced TNF-alpha-mediated mouse lung lesions and endotoxic shock
Ke et al. Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis
Kubo et al. Protective effects of Mkl1/2 against lipodystrophy and muscle atrophy via PI3K/AKT-independent FoxO repression
JP6659250B2 (ja) 癌の検査方法、癌細胞増殖阻害剤、抗癌剤及び抗癌剤のスクリーニング方法
JP2018177658A (ja) 去勢抵抗性前立腺癌の治療
CN119082287A (zh) 去乙酰化酶sirt2的应用及调控rna病毒感染的药物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141128

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180424

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190718

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190926

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190718

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I